AB&B BIO-TECH-B (02627) announced that the company has entered into a strategic cooperation agreement with Watson Biotech (Hong Kong) Limited concerning the overseas market expansion of a subunit influenza vaccine. According to the strategic cooperation agreement, the two parties will engage in deep collaboration on the overseas market registration, sales, and commercialization of the Group's developed products. The core product for this overseas expansion is the Group's independently developed trivalent subunit influenza vaccine (Huierkangxin 3). This product received market approval in January 2026 and is the first and only trivalent subunit flu vaccine in China approved for use in individuals aged 6 months and above.

The Board of Directors believes that Hong Kong Watson is a pioneer in overseas business expansion with extensive international operation experience. Through this collaboration, the company will leverage the overseas market resources and mature distribution network that Hong Kong Watson has cultivated over many years to accelerate the entry of its products into markets in Southeast Asia, Latin America, the Middle East, and other regions in the Southern Hemisphere.